简介:病人男性,46岁,左上腹部疼痛不适、消瘦1月,于2002年1月20日入院。病人自述1个月前开始左上腹部隐痛不适,呈持续性疼痛,夜间加重,伴有乏力,体重下降明显(约10kg)。无其它不适。查体:未触及表浅淋巴结肿大。腹部膨隆,以左侧为主。可触及脾脏肿大,脾下界达左肋下约3cm。向右越过中线2cm,质韧,边界清,触痛明显,推之不移动。B超:肝脏正常。脾脏体积显著增大,30cm×28cm×15cm大小,
简介:目的比较苦参素联合拉米夫定与单用拉米夫定治疗拉米夫定撤药性慢性乙型肝炎治疗效果.方法52例HBeAg阳性拉米夫定撤药性慢性乙型肝炎患者,随机分为治疗组30例和对照组22例,治疗组应用苦参素联合拉米夫定,对照组单用拉米夫定,疗程6个月.结果治疗结束时,治疗组ALT复常率(100%),明显高于对照组(86.7%);停药半年后ALT复常率(86.7%),明显高于对照组(63.6%).治疗组血清HBeAg阴转率(63.3%)明显高于对照组(22.7%);治疗组停药半年后HBeAg阴转率(53.3%)明显高于对照组(9.0%).治疗组血清HB以g血清转换率(46.7%)明显高于对照组(9.0%);停药半年后血清HBeAg血清转换率治疗组(36.7%)明显高于对照组(4.5%).治疗组血清HBVDNA阴转率(96.7%)明显高于对照组(77.3%);治疗组停药半年后血清HBVDNA持续阴转率(76.7%)明显高于对照组(40.9%).结论苦参素联合拉米夫定治疗慢性乙型肝炎优于单用拉米夫定治疗,对拉米夫定撤药性肝炎有一定的疗效.
简介:目的探讨PreS1抗原检测的临床价值。方法采用酶联免疫吸附试验法检测421例慢性乙型肝炎患者血清PreS1抗原和HBV标记物;采用荧光定量PCR法检测HBVDNA。结果在421例慢性乙型肝炎患者中,HBVDNA阳性者367例,其中PreS1Ag阳性者188例(51.2%),HBeAg阳性者119例(32.4%),后两者有显著性差异(P〈0.01);在高HBVDNA载量(105~107copies/ml和〉107copies/ml)组患者中,PreS1Ag阳性率(60.2%,60.0%)显著高于HBVDNA阴性组(33.3%)和低载量(103~105copies/ml)组(41.9%,P〈0.01);但在421例患者中,PreS1Ag阳性率(48.9%)低于HBVDNA(87.2%,P〈0.01)。结论PreS1Ag能够较HBeAg更好地反映HBV在体内的复制状态,但尚不能代替HBVDNA的检测。
简介:INTRODUCTIONInChina,liverfibrosisinmostpatientsresultedfromthevirusesofhepatitisB.Bothanti-virusandanti-fibrosisshouldbeconsideredindesigningaprogramforthetreatmentofliverfibrosis.Therefore,40casesofliverfibrosisduetohepatitisBweretreatedbyusingIFN-α1andtraditionalmedicinalpreparationsfromFebruary1994toApril1996.Goodcurativeeffectwasachieved.
简介:AIMTotestwhetherNox1playsaroleintyphlitisinducedbySalmonellaentericaserovarTyphimurium(S.Tm)inamousemodel.METHODSEight-week-oldmalewild-type(WT)andNox1knockout(KO)C57BL6/J(B6)micewereadministeredmetronidazolewaterfor4dtomakethemsusceptibletoS.Tminfectionbytheoralroute.Themiceweregivenplainwaterandadministeredwith4differentdosesofS.Tmbyoralgavage.Themicewerefollowedforanother4d.Fromthetimeofthemetronidazoleapplication,themicewereobservedtwicedailyandweigheddaily.Theileum,cecumandcolonwereremovedforsamplingatthefourthdaypost-inoculation.PortionsofallthreetissueswerefixedforhistologyandplacedinRNAlaterformRNA/cDNApreparationandquantitativereal-timePCR.ThecontentsofthececumwererecoveredforestimationofS.TmCFU.RESULTSWefoundNox1-knockout(Nox1-KO)micewerenotmoresensitivetoS.TmcolonizationandinfectionthanWTB6mice.Thisconclusionisbasedonthefollowingobservations:(1)S.Tm-infectioninducedsimilarweightlossinNox1-KOmicecomparedtoWTmice;(2)thesameS.TmCFUwasrecoveredfromthececalcontentofNox1-KOandWTmiceregardlessoftheinoculationdose,exceptthelowestinoculationdose(2×106CFU)forwhichtheNox1-KOhadone-loglowerCFUthanWTmice;(3)thereisnodifferenceincecalpathologybetweenWTandNox1-KOgroups;and(4)therearenoS.Tminfection-inducedchangesingeneexpressionlevels(IL-1b,TNF-α,andDuox2)betweenWTandNox1-KOgroups.TheAlpigeneexpressionwasmoresuppressedbyS.TmtreatmentinWTthantheNox1-KOcecum.CONCLUSIONNox1doesnotprotectmicefromS.Tmcolonization.Nox1-KOprovidesaveryminorprotectiveeffectagainstS.Tminfection.UsingNOX1-specificinhibitorsforcolitistherapyshouldnotincreaserisksinbacterialinfection.
简介:目的探讨RNA干扰(RNAi)技术沉默Bmi-1基因表达对人大肠癌细胞株LOVO增殖和侵袭力的影响及机制。方法将化学法合成的针对Bmi-1mRNA不同位点设计的3对siRNA序列(siR-NA1~3)和1对带有荧光标记的FAM-siRNA(siRNA4)转染至人大肠癌LOVO细胞,荧光显微镜下观察siRNA的转染效率,QRT-PCR检测Bmi-1mRNA表达抑制作用,WesternBlot检测Bmi-1蛋白表达变化,MTT法检测LOVO细胞体外增殖变化,小室侵袭实验检测LOVO细胞侵袭能力。结果利用荧光标记的Oligo观察到siRNA转染效率达70%。siRNA1对mRNA表达抑制率最高,从而筛选出沉默效应最强的siRNA序列为siRNA1。siRNA1转染组LOVO细胞Bmi-1蛋白表达,增殖及侵袭力明显低于阴性对照组和空白对照组(P〈0.05)。结论化学合成的靶向Bmi-1siRNA转染人大肠癌LOVO细胞能有效抑制Bmi-1的mRNA和蛋白质表达水平,Bmi-1基因的RNA干扰可有效抑制人大肠癌LOVO细胞的增殖和侵袭能力。